Regeneron reports second quarter 2021 financial and operating results

Tarrytown, n.y., aug. 5, 2021 /prnewswire/ --   second quarter 2021 revenues increased 163% to $5.14 billion versus second quarter 2020 including $2.76 billion attributable to regen-cov tm(2) ; revenues excluding regen-cov (1)(2) increased 22% second quarter 2021 eylea® u.s. net sales increased 28% versus second quarter 2020 to a record $1.42 billion second quarter 2021 dupixent® global net sales (3) , which are recorded by sanofi, increased 59% to $1.50 billion versus second quarter 2020 second quarter 2021 gaap diluted eps was $27.97 and non-gaap diluted eps (1) was $25.80 fda updated regen-cov emergency use authorization (eua) with lower dose, subcutaneous administration, and post-exposure prophylaxis regen-cov phase 3 recovery trial in hospitalized patients with severe covid-19 met primary outcome reported that dupixent significantly improved itch and hives in patients with chronic spontaneous urticaria, marking the fifth disease to show positive pivotal results phase 3 trial of libtayo® combined with chemotherapy stopped early due to significant improvement in overall survival in patients with first-line advanced non-small cell lung cancer regeneron pharmaceuticals, inc. (nasdaq: regn) today announced financial results for the second quarter of 2021 and provided a business update.
REGN Ratings Summary
REGN Quant Ranking